Market Place
Sourcing Support
Otsuka Updates on Sibeprenlimab for IgA Nephropathy
19 Nov 2024 //
BUSINESSWIRE
Otsuka forms joint venture to boost IV solution supply
14 Nov 2024 //
FIERCE PHARMA
ICU Medical & Otsuka Announce Joint Venture to Boost IV in America
12 Nov 2024 //
PR NEWSWIRE
Otsuka`s kidney disease drug improves UPCR levels in phase 3 trial
23 Oct 2024 //
BUSINESSWIRE
Otsuka tots up 6-figure unpaid salary for dementia caregivers
15 Oct 2024 //
FIERCE PHARMA
Study Finds Family Caregivers Would Earn Six Figures If Paid A Salary
14 Oct 2024 //
BUSINESSWIRE
OPH & Amalgam Rx Announce Digital Support For Alzheimer’s Caregiver
07 Oct 2024 //
BUSINESSWIRE
Aurinia Announces Japan Approval of LUPKYNIS® for Lupus Nephritis
24 Sep 2024 //
BUSINESSWIRE
FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections
14 Sep 2024 //
FIERCE PHARMA
Japan`s Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
01 Aug 2024 //
PRESS RELEASE
UK partnership aims to support NHS use of depression app News
29 Jul 2024 //
PHARMAPHOROUM
Otsuka Announce FDA Acceptance of sNDA for Brexpiprazole and Sertraline
25 Jun 2024 //
BUSINESSWIRE
Otsuka mauled by ad body for `unacceptable` transparency failing
06 Jun 2024 //
FIERCE PHARMA
Otsuka, Lundbeck: Brexpiprazole Plus Sertraline Data In PTSD Presented
28 May 2024 //
BUSINESSWIRE
Otsuka to Terminate Development of AVP-786
22 May 2024 //
BUSINESSWIRE
Otsuka gives up on Alzheimer`s drug after 2nd failed trial
22 May 2024 //
FIERCE PHARMA
Lundbeck blames DTC blackout for slowdown in Rexulti growth
16 May 2024 //
FIERCE PHARMA
Enforcement Report - Week of May 1, 2024
01 May 2024 //
FDA
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry
04 Apr 2024 //
BUSINESSWIRE
FDA clears Otsuka, Click`s prescription app for depression
03 Apr 2024 //
FIERCE BIOTECH
Otsuka and Click Thera Announce the FDA Clearance of Rejoyn for the MDD Symptoms
01 Apr 2024 //
BUSINESSWIRE
Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
28 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
18 Mar 2024 //
BUSINESSWIRE
Otsuka and Sumitomo Revise License Agreement
15 Mar 2024 //
PRESS RELEASE
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors
06 Mar 2024 //
PRESS RELEASE
Otsuka Pharma enters into $30 M investment contract with AN Venture Partners
29 Feb 2024 //
BIOSPECTRUM ASIA
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation
16 Feb 2024 //
BUSINESSWIRE
Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"
13 Feb 2024 //
PRESS RELEASE
Otsuka`s drug for Alzheimer`s disease agitation fails in late stage study
13 Feb 2024 //
BUSINESSWIRE
Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin
09 Feb 2024 //
PRESS RELEASE
Otsuka and Jolly Good to Start Delivery of FACEDUO Content
08 Feb 2024 //
PRESS RELEASE
Otsuka Pharmaceutical Achieves "Silver" Level Certification
23 Jan 2024 //
PRESS RELEASE
Otsuka pays Ionis $65M for European rights to rare disease drug
19 Dec 2023 //
FIERCE BIOTECH
Ionis announces European licensing agreement with Otsuka for donidalorsen
18 Dec 2023 //
PR NEWSWIRE
Otsuka Pharmaceutical Introduces New "Self-Care Leave" System
14 Dec 2023 //
PRESS RELEASE
D&I Award 2023 - Otsuka Pharmaceutical Designated as "Best Workplace"
13 Dec 2023 //
PRESS RELEASE
Pharmavite acquires Bonafide Health, a provider of women`s health products
01 Dec 2023 //
PRESS RELEASE
Otsuka Pharmaceutical to Sponsor Thematic Project "Resonance of Lives"
30 Nov 2023 //
PRESS RELEASE
Astex Has Third Approval Success in a Drug Discovery Collaboration
22 Nov 2023 //
PRESS RELEASE
Aurinia Announces Collaboration Partner Otsuka Filed NDA for LUPKYNIS
13 Nov 2023 //
BUSINESSWIRE
Otsuka Submits New Drug Application in Japan for Voclosporin
10 Nov 2023 //
PRESS RELEASE
Selected as METI`s "Model Project for the Promotion of PHR Services" Launch of a Healthcare Service
08 Nov 2023 //
PRESS RELEASE
MIREVO® Obtains Regulatory Approval, a First in Japan
08 Nov 2023 //
PRESS RELEASE
US FDA approves Otsuka`s blood pressure treatment device for use
08 Nov 2023 //
REUTERS
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023
07 Nov 2023 //
PRESS RELEASE
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab
06 Nov 2023 //
PRESS RELEASE
Otsuka Announces Personnel Changes
06 Nov 2023 //
PRESS RELEASE
Otsuka, Missy Franklin team up for rare kidney disease campaign
03 Nov 2023 //
FIERCE PHARMA
Journal of Medicine Publishes Complete Results of Phase 2 Trial of Sibeprenlimab
02 Nov 2023 //
BUSINESSWIRE
Otsuka partners with former Olympic swimmer on kidney disease campaign
02 Nov 2023 //
ENDPTS
Otsuka reports positive results from two phase 3 trials of centanafadine
30 Oct 2023 //
PHARMABIZ
Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine
27 Oct 2023 //
BUSINESSWIRE
Otsuka’s ADHD asset succeeds in registrational trials with children and teens
27 Oct 2023 //
ENDPTS
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
26 Oct 2023 //
PRESS RELEASE
Regulates moisture in the stratum corneum for skin care experience
03 Oct 2023 //
PRESS RELEASE
Otsuka and Astex announce that the European Commission has approved INAQOVI
19 Sep 2023 //
BUSINESSWIRE
Otsuka Enters into Agreement with Japan Association of Public Welfare Workers
15 Sep 2023 //
PRESS RELEASE
Otsuka pens AAV deal with Shape Therapeutics for eye gene therapies
08 Sep 2023 //
ENDPTS
